NCT07120828View on ClinicalTrials.gov

The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity

PHASE4RecruitingINTERVENTIONAL
Enrollment

260

Participants

Timeline

Start Date

July 15, 2025

Primary Completion Date

March 1, 2026

Study Completion Date

May 1, 2026

Conditions
Type 2 DiabetesObese DiabeticsObese Patients (BMI ≥ 30 kg/m²)
Interventions
DRUG

Empagliflozin (oral)

Empagliflozin 10 mg oral tablet administered once daily for 6 months.

DRUG

Dapagliflozin (DAPA)

Dapagliflozin 10 mg oral tablet administered once daily for 6 months

DRUG

Metfomin

metformin 500-1000 mg/day administered as part of standard care, based on clinical indication.

Trial Locations (1)

44001

RECRUITING

Epu, Erbil

All Listed Sponsors
collaborator

Kurdistan Higher Council of Medical Specialties

OTHER

lead

Erbil Polytechnic University

OTHER